Ruane Clinical Research Group | Los Angeles, CA

Research site

(Unclaimed)

Location

5901 W Olympic Boulevard, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Budigalimab

JNJ-73763989

Bictegravir

JNJ-56136379

Ribavirin

Selonsertib

ABBV-382

Islatravir

Sofosbuvir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 27 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV Infections

Drug: Lenacapavir Tablet

Drug: Zinlirvimab

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling

Human Immuno-deficiency Virus (HIV) Disease

Drug: Budigalimab

Drug: ABBV-382

Locations recently updated

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: B/F/TAF

Drug: ISL

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting

Primary Biliary Cirrhosis

Drug: Elafibranor 80mg

Drug: Placebo

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: PTM F/TDF

Drug: Placebo SC LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling

HIV-1-infection

Drug: B/F/TAF

Drug: Placebo to match B/F/TAF

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo